TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22782052

Group type: EXPERIMENTAL
Intervention: Castor oil extract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Polymyxin B
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2) and 2% chlorhexidine gel (CHX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 60
Study: 19475583

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications (specific medications not detailed)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Candidate gene analysis (128 candidate genes studied)
Number of subjects: 710
Study: 18054633

Group type: EXPERIMENTAL
Intervention: Scleral buckling surgery (SB)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Primary vitrectomy (PPV)
Number of subjects: 681
Study: 15843336

Group type: EXPERIMENTAL
Intervention: Interventions that modulate suicide ideation (specific interventions not detailed in the abstract)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study: 12163424

Group type: EXPERIMENTAL
Intervention: Aspirin plus moderate-intensity coumarin (3-month regimen)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 308
Study: 9564799

Group type: EXPERIMENTAL
Intervention: 200 microg/day fluticasone propionate (FP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 220 microg/day triamcinolone acetonide (TAA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 336 microg/day beclomethasone dipropionate (BDP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9050533

Group type: EXPERIMENTAL
Intervention: Nitrous oxide pneumoperitoneum
Number of subjects: 105

Group type: COMPARATOR
Intervention: Carbon dioxide pneumoperitoneum
Number of subjects: 105
Study: 3046350

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (5 mg/kg every eight hours) for five days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 30069912

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 13
Study: 30082261

Group type: EXPERIMENTAL
Intervention: BuMA Supreme stent
Number of subjects: 72

Group type: COMPARATOR
Intervention: XIENCE stent
Number of subjects: 72
Study: 27012401

Group type: EXPERIMENTAL
Intervention: Adenosine-stress cardiac magnetic resonance (CMR) imaging
Number of subjects: 117
Study: 24682356

Group type: EXPERIMENTAL
Intervention: Active self-correction and task-oriented exercises
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional spinal exercises
Number of subjects: 110
Study: 21450569

Group type: EXPERIMENTAL
Intervention: Exercise training for 4 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 39
Study: 20082696

Group type: EXPERIMENTAL
Intervention: Class-based exercise (FAME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based exercise (OEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17327249

Group type: EXPERIMENTAL
Intervention: Intravaginal continence pessary
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (including pelvic floor muscle training and exercise and bladder control strategies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of intravaginal continence pessary and behavioral therapy
Number of subjects: 0
Study: 16291891

Group type: EXPERIMENTAL
Intervention: Delta(9)‐tetrahydrocannabinol (Delta(9)‐THC)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Cannabis extract
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study: 11943517

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine 5-mg/24-hour patch
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 36
Study: 9718784

Group type: EXPERIMENTAL
Intervention: Double aspirative drain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double open Silastic drain
Number of subjects: 0
Study: 7795367

Group type: EXPERIMENTAL
Intervention: Single transvaginal ultrasonographic evaluation with plasma hCG determination
Number of subjects: 260

Group type: COMPARATOR
Intervention: Viable pregnancy group
Number of subjects: 260
Study: 2646301

Group type: EXPERIMENTAL
Intervention: HDCS + i.m. HRIG 20 IU/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: i.v. HRIG alone 15 IU/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HDCS + i.v. HRIG 15 IU/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HDCS + HRIG 5 IU/kg i.v. plus 10 IU/kg i.m.
Number of subjects: 30

Group type: COMPARATOR
Intervention: HDCS alone
Number of subjects: 30
Study: 1100299

Group type: EXPERIMENTAL
Intervention: Marihuana (25 mug/kg THC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium secobarbital (150 mg/70 kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of marihuana and secobarbital
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6102180

Group type: EXPERIMENTAL
Intervention: Cefazolin (3 doses of 1 g each)
Number of subjects: 515
Study: 31192710

Group type: EXPERIMENTAL
Intervention: Sleep hygiene education for 10 minutes via video, applied for 3 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sleep hygiene education vs Control
Number of subjects: 46
Study: 28645737

Group type: EXPERIMENTAL
Intervention: Alfapump® (AP)
Number of subjects: 60
Study: 26372927

Group type: EXPERIMENTAL
Intervention: CT and NG infection
Number of subjects: 1373

Group type: EXPERIMENTAL
Intervention: CT infection
Number of subjects: 1373
Study: 23422464

Group type: EXPERIMENTAL
Intervention: Boxing training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional exercise
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 21175792

Group type: EXPERIMENTAL
Intervention: Triple therapy with probiotic-containing yogurt (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium longum, and Streptococcus thermophilus)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Triple therapy without yogurt (control group)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Triple therapy with probiotic-containing yogurt
Number of subjects: 337
Study: 19752879

Group type: EXPERIMENTAL
Intervention: 5HTP-Nat Exts
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17361128

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose, 15 mg maintenance dose) with ketoconazole (400 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, 75 mg maintenance dose) with ketoconazole (400 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose, 75 mg maintenance dose) without ketoconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel (60 mg loading dose, 15 mg maintenance dose) without ketoconazole
Number of subjects: 0
Study: 15375502

Group type: EXPERIMENTAL
Intervention: HCT group (1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: HCT group
Number of subjects: 136

Group type: COMPARATOR
Intervention: CMFT group (CMF + tamoxifen)
Number of subjects: 136
Study: 11453171

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 7
Study: 10204352

Group type: EXPERIMENTAL
Intervention: Immunosorption (IS) with DNA-containing active carbon
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonselective hemosorption (NHS) with carbon
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control carbon (NHS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both IS and NHS
Number of subjects: 22
Study: 8144266

Group type: EXPERIMENTAL
Intervention: 0.85 g/kg dose of alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2974411

Group type: EXPERIMENTAL
Intervention: 15 percent propylene glycol, 50 percent ethanol, and 35 percent water
Number of subjects: 39

Group type: COMPARATOR
Intervention: 50 percent ethanol and 50 percent water
Number of subjects: 39
Study: 30772070

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR (PXVX0200) 1 × 10^9 CFU
Number of subjects: 2979

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2979

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR (PXVX0200)
Number of subjects: 2979
Study: 28787737

Group type: EXPERIMENTAL
Intervention: Diet I (low in carbohydrates)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Diet II (low in fat)
Number of subjects: 283
Study: 26418666

Group type: EXPERIMENTAL
Intervention: SRP + L (scaling and root planing plus adjunctive laser therapy)
Number of subjects: 22

Group type: COMPARATOR
Intervention: SRP (scaling and root planing alone)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SRP + L
Number of subjects: 22

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 22
Study: 23223117

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IV ketamine (group K)
Number of subjects: 190
Study: 21669126

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon β‐1a (IM IFN‐β‐1a)
Number of subjects: 286
Study: 19136898

Group type: EXPERIMENTAL
Intervention: Rapid discontinuation of prednisone (RDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical controls with maintenance prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RDP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance prednisone
Number of subjects: 0
Study: 16962524

Group type: EXPERIMENTAL
Intervention: 1 mg granisetron (Group A, n=70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Saline solution (Group B, n=70)
Number of subjects: 140
Study: 27932764

Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10% intralipid
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 18
Study: 10352054

Group type: EXPERIMENTAL
Intervention: Breastfeeding support according to a breastfeeding protocol for twins
Number of subjects: 18

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Number of subjects: 18
Study: 8766398

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with piritramide (bolus 2.5 mg, blocking time 20 minutes, no basal infusion)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with bupivacaine 0.5% and intravenous PCA (same parameters as group 1) plus continuous epidural infusion of bupivacaine 0.1875% at 8 ml/h
Number of subjects: 74
Study: 1928855

Group type: COMPARATOR
Intervention: No haemodilution (Control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acute isovolaemic haemodilution (AIH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 7201271

Group type: EXPERIMENTAL
Intervention: Fentanyl, 8 micrograms/kg with thiopental, 3 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Thiopental, 6 mg/kg alone
Number of subjects: 36
Study: 31918574

Group type: EXPERIMENTAL
Intervention: Kinesiotape plus exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham kinesiotape plus exercise
Number of subjects: 60
Study: 31344787

Group type: EXPERIMENTAL
Intervention: 12-week combined ergonomics and neck/shoulder strengthening exercise intervention (EET)
Number of subjects: 177

Group type: COMPARATOR
Intervention: 12-week combined ergonomics and health promotion intervention (EHP)
Number of subjects: 177
Study: 29663701

Group type: EXPERIMENTAL
Intervention: RAL 0.1% cream
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RAL 0.05% cream
Number of subjects: 40
Study: 26850746

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (∼1.8 g/day) for ∼14 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 25208366

Group type: EXPERIMENTAL
Intervention: Colgate Total toothpaste (0.3% triclosan, 2% copolymer, 0.243% sodium fluoride)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75
Study: 22706692

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 89784

Group type: COMPARATOR
Intervention: Conventional Papanicolaou (CP) smear
Number of subjects: 89784
Study: 20403018

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (mean = 0.12 g% breath alcohol concentration)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 18316629

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (plasma glucose increased to 12 mM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia (plasma insulin increased to 400 pmol/L)
Number of subjects: 24
Study: 16273794

Group type: EXPERIMENTAL
Intervention: ACR Core Data Set
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled index of patient self-report questionnaire measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 12610003

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg daily (Irb150)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg daily (Irb300)
Number of subjects: 43
Study: 10480767

Group type: EXPERIMENTAL
Intervention: Humalog Mix25
Number of subjects: 89

Group type: COMPARATOR
Intervention: human insulin 30/70
Number of subjects: 89
Study: 8602660

Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg‐1 cisatracurium
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg‐1 cisatracurium
Number of subjects: 20
Study: 1768553

Group type: EXPERIMENTAL
Intervention: Inspiratory pressure support jet ventilation (IPSTGIT)
Number of subjects: 10
Study: 6461281

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 mcg from a metered dose inhaler)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31851256

Group type: EXPERIMENTAL
Intervention: Educational intervention via telephone for 3 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional follow-up (Control Group)
Number of subjects: 101
Study: 28781108

Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg once weekly for 48 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 26687300

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lamotrigine without folic acid
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lamotrigine with folic acid
Number of subjects: 202

Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 202
Study: 24953276

Group type: EXPERIMENTAL
Intervention: ROLL (Radioguided Occult Lesion Localization)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IOUS (Intraoperative Ultrasonography)
Number of subjects: 20
Study: 22908773

Group type: EXPERIMENTAL
Intervention: Potassium citrate and dry extract of Agropyrum repens (CalcoMEV) at the dose of 24 mEq of potassium citrate and 100 mg of dry extract of Agropyrum repens bis in die
Number of subjects: 50

Group type: COMPARATOR
Intervention: Potassium citrate at a dose of 20 mEq ter in die
Number of subjects: 50
Study: 21189142

Group type: EXPERIMENTAL
Intervention: Verum laser acupuncture
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 34
Study: 17661767

Group type: EXPERIMENTAL
Intervention: Oral sotalol (80 mg twice daily) and magnesium supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (matched, n = 844)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Noncompliant patients
Number of subjects: 49
Study: 16049806

Group type: EXPERIMENTAL
Intervention: GSTT1 null genotype
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: GSTT1 null genotype and formerly smoked
Number of subjects: 676

Group type: COMPARATOR
Intervention: Current smokers who smoked 20 cigarettes or more per day
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Presence of three or more putative at risk genotypes
Number of subjects: 676
Study: 11940138

Group type: EXPERIMENTAL
Intervention: Warm 0.2% chlorhexidine rinse at 47 degrees C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cold 0.2% chlorhexidine rinse at 18 degrees C
Number of subjects: 10
Study: 10394161

Group type: EXPERIMENTAL
Intervention: Microcirculatory classification (good, intermediate, poor)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Poor microcirculatory group
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intermediate microcirculatory group
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Good microcirculatory group
Number of subjects: 111
Study: 1390141

Group type: EXPERIMENTAL
Intervention: 0.05% solution of a commercial dish-washing product (three times/day, for 15 min, at 37 degrees C) for 3 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Warm tap-water (control experiment)
Number of subjects: 18
Study: 3162108

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study: 31647496

Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab, 0.5 mg, at baseline and as frequently as every 4 weeks
Number of subjects: 213

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) at baseline
Number of subjects: 213
Study: 29800014

Group type: EXPERIMENTAL
Intervention: Solar-powered oxygen delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oxygen delivery using compressed oxygen cylinders
Number of subjects: 0
Study: 27362442

Group type: EXPERIMENTAL
Intervention: ACE (2.3 g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26176940

Group type: EXPERIMENTAL
Intervention: Standard EC-MPS dosing (1440 mg/day) with low exposure to CsA (4.5 mg/kg/day for low risk DGF, 2.5 mg/kg/day for high risk DGF)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard EC-MPS dosing (1440 mg/day) with low exposure to CsA
Number of subjects: 162
Study: 23714268

Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg three times per week for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 21621886

Group type: EXPERIMENTAL
Intervention: Low-volume enteral supplement containing key nutrients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Diluted standard nutrition solution
Number of subjects: 58
Study: 18291290

Group type: EXPERIMENTAL
Intervention: History of substance use disorder (SUD)
Number of subjects: 127

Group type: COMPARATOR
Intervention: No history of substance use disorder (SUD)
Number of subjects: 127
Study: 16824845

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Heparin plus GPIIb/IIIa inhibitors
Number of subjects: 1351
Study: 12959730

Group type: EXPERIMENTAL
Intervention: Low activity radioactive stenting (n = 18)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: High activity radioactive stenting (n = 26)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cold-end radioactive stenting (n = 18)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Catheter-based radiation (Novoste Betacath (n = 39) and Guidant (n = 27))
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (Percutaneous transluminal coronary angioplasty with (n = 48) and without (n = 22) stent implantation)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 128
Study: 10836008

Group type: EXPERIMENTAL
Intervention: SLNB (Sentinel Lymph Node Biopsy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN‐α(2b)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose IFN‐α(2b)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RT‐PCR detection of tyrosinase in SLNs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy or adjuvant IFN‐α(2b) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RT‐PCR analysis of peripheral blood and bone marrow
Number of subjects: 0
Study: 9643529

Group type: EXPERIMENTAL
Intervention: GMDP solution (0.5-1.0 mg daily)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GMDP solution (1.5 mg/kg daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GMDP solution
Number of subjects: 63
Study: 7621303

Group type: COMPARATOR
Intervention: Pravastatin (40mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nicotinic acid (1500mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin 20mg/day and Nicotinic acid 1000mg/day)
Number of subjects: 44
Study: 3258558

Group type: EXPERIMENTAL
Intervention: Intravenous human calcitonin-gene-related peptide (hCGRP) 2.5 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous human calcitonin-gene-related peptide (hCGRP) 10 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous human calcitonin-gene-related peptide (hCGRP) 25 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31584311

Group type: EXPERIMENTAL
Intervention: Dried apple (120 kcal serving, twice daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control snack (muffin, 120 kcal serving, twice daily)
Number of subjects: 38
Study: 30043713

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 285

Group type: COMPARATOR
Intervention: Prostatectomy
Number of subjects: 285
Study: 24726378

Group type: EXPERIMENTAL
Intervention: Microfracture-based cartilage repair treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pre-existing conditions
Number of subjects: 78
Study: 24198887

Group type: EXPERIMENTAL
Intervention: Periodontal therapy (scaling & root planing) in Group B
Number of subjects: 40

Group type: COMPARATOR
Intervention: No periodontal treatment in Group A
Number of subjects: 40
Study: 18665846

Group type: EXPERIMENTAL
Intervention: Research during acute epidemics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community engagement, public notification, and good information management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efforts to maintain individual consent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of data safety management boards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhancing the social value of research
Number of subjects: 0